At a glance
ClinicalIndex Comparison RecordN/ACompleted· 172 enrolled
Drug / intervention
L - Antineoplastic and immunomodulating agents +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.
In Brief
An observational study evaluating L - Antineoplastic and immunomodulating agents, L01 - Antineoplastic agents, and 3 other interventions for Idiopathic Pulmonary Fibrosis. Completed, enrolled 172 participants across 1 site.
Detailed Summary
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish Pulmonology Services.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedSep 13, 2017
Enrollment StartOct 24, 2017
Primary CompletionJun 7, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.8 years ago
Interventions
L - Antineoplastic and immunomodulating agentsdrug
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agentsdrug
L01 - Antineoplastic agents
L01X - Other antineoplastic agentsdrug
L01X - Other antineoplastic agents
L01XE - Protein kinase inhibitorsdrug
L01XE - Protein kinase inhibitors
L01XE31 - Nintedanibdrug
L01XE31 - Nintedanib